ClinicalTrials.gg
Not yet recruitingNCT07526402taVNS-FREQUpdated Apr 16, 2026

Different Frequency Applications of Transcutaneous Auricular Vagus Nerve Stimulation in Healthy Individuals

An interventional study of Sham taVNS and taVNS 10 Hz in Healthy Volunteers, sponsored by Sinop University. Not yet recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-16.

Sponsored by Sinop University · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Primary completion was expected by May 2026, 6 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Study summary

This randomized, participant-blinded, sham-controlled crossover study aims to investigate the acute effects of different frequency applications of transcutaneous auricular vagus nerve stimulation (taVNS) on autonomic physiological responses in healthy adults. Participants will receive sham (0 Hz), 10 Hz, 25 Hz, 50 Hz, and 100 Hz taVNS in separate sessions with washout periods between visits. Heart rate variability, blood pressure, pulse rate, respiratory rate, and subjective discomfort will be assessed before and after each intervention session.

Read the detailed description

The vagus nerve is a major regulator of the parasympathetic branch of the autonomic nervous system. Transcutaneous auricular vagus nerve stimulation (taVNS) is a non-invasive neuromodulation technique applied to auricular regions innervated by the auricular branch of the vagus nerve. Although taVNS has been reported to modulate autonomic function, the acute physiological effects of different stimulation frequencies remain insufficiently characterized.

This study is designed as a randomized, participant-blinded, sham-controlled crossover trial in healthy adults aged 18 to 40 years. Each participant will undergo five intervention conditions in randomized order: sham (0 Hz), 10 Hz, 25 Hz, 50 Hz, and 100 Hz taVNS. Sessions will be separated by 48 to 72 hours to minimize carryover effects. Each stimulation session will last 10 minutes.

Primary autonomic outcomes will be derived from heart rate variability parameters obtained using a Polar H10 chest strap and analyzed with Kubios HRV software. Secondary physiological outcomes will include systolic and diastolic blood pressure, pulse rate, respiratory rate, and subjective discomfort measured using a visual analog scale. The study aims to identify frequency-specific autonomic response profiles and to evaluate whether respiratory rate influences heart rate variability changes associated with taVNS.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Sinop University is the lead sponsor of 35 studies on the registry; 13 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adults aged 18 to 40 years
  • No known neurological, cardiovascular, respiratory, or metabolic disease
  • Able to understand study procedures and provide written
  • No active infection, open wound, or dermatological lesion in the ear region that would interfere with taVNS application
  • Willing and able to attend all study visits

Exclusion criteria

Exclusion Criteria:

  • History of cardiac arrhythmia, pacemaker, or any implanted electronic medical device History of hypertension, diabetes, chronic pulmonary disease, epilepsy, or systemic disease affecting autonomic nervous system function
  • Regular use of medications that may affect autonomic function (e.g., beta-blockers, antidepressants, antiarrhythmics)
  • Intense physical exercise within the previous 24 hours
  • High caffeine or alcohol intake within 12 hours prior to assessment
  • Active smoking on the assessment day
  • Pregnancy or suspected pregnancy
  • Severe discomfort during stimulation (VAS >= 7), dizziness, nausea, or unwillingness to continue
  • Any condition judged by the investigators to make participation unsuitable'
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
36 participants (estimated)

Study arms

  • Sham comparator
    Sham taVNS

    Participants receive sham stimulation during one study session.

    Device: Sham taVNS

  • Experimental
    taVNS 10 Hz

    Participants receive active transcutaneous auricular vagus nerve stimulation at 10 Hz during one study session.

    Device: taVNS 10 Hz

  • Experimental
    taVNS 25 Hz

    Participants receive active transcutaneous auricular vagus nerve stimulation at 25 Hz during one study session.

    Device: taVNS 25 Hz

  • Experimental
    taVNS 50 Hz

    Participants receive active transcutaneous auricular vagus nerve stimulation at 50 Hz during one study session.

    Device: taVNS 50 Hz

  • Experimental
    taVNS 100 Hz

    Participants receive active transcutaneous auricular vagus nerve stimulation at 100 Hz during one study session.

    Device: taVNS 100 Hz

Interventions

  • DeviceSham taVNS

    Sham stimulation is delivered under conditions similar to active taVNS without meaningful vagal stimulation.

  • DevicetaVNS 10 Hz

    Active transcutaneous auricular vagus nerve stimulation applied for 10 minutes at 10 Hz.

  • DevicetaVNS 25 Hz

    Active transcutaneous auricular vagus nerve stimulation applied for 10 minutes at 25 Hz.

  • DevicetaVNS 50 Hz

    Active transcutaneous auricular vagus nerve stimulation applied for 10 minutes at 50 Hz.

  • DevicetaVNS 100 Hz

    Active transcutaneous auricular vagus nerve stimulation applied for 10 minutes at 100 Hz.

06

What researchers measure

Primary outcomes

  1. Change in Root Mean Square of Successive Differences (RMSSD)

    Change in the root mean square of successive differences (RMSSD) from pre-intervention to post-intervention under each stimulation condition.

    Time frame: Immediately before and immediately after each 10-minute intervention session

  2. Change in High-Frequency Heart Rate Variability (HF-HRV)

    Change in high-frequency heart rate variability (HF-HRV) from pre-intervention to post-intervention under each stimulation condition.

    Time frame: Immediately before and immediately after each 10-minute intervention session

Secondary outcomes

  1. Change in Standard Deviation of Normal-to-Normal RR Intervals (SDNN)

    Change in the standard deviation of normal-to-normal RR intervals (SDNN) from pre-intervention to post-intervention under each stimulation condition.

    Time frame: Immediately before and immediately after each 10-minute intervention session

  2. Change in Low-Frequency (LF) Power

    Change in low-frequency (LF) power of heart rate variability from pre-intervention to post-intervention under each stimulation condition.

    Time frame: Immediately before and immediately after each 10-minute intervention session

  3. Change in LF/HF Ratio

    Change in the ratio of low-frequency to high-frequency heart rate variability (LF/HF ratio) from pre-intervention to post-intervention under each stimulation condition.

    Time frame: Immediately before and immediately after each 10-minute intervention session

  4. Change in Systolic Blood Pressure

    Change in systolic blood pressure from pre-intervention to post-intervention under each stimulation condition.

    Time frame: Immediately before and immediately after each 10-minute intervention session

  5. Change in Diastolic Blood Pressure

    Change in diastolic blood pressure from pre-intervention to post-intervention under each stimulation condition.

    Time frame: Immediately before and immediately after each 10-minute intervention session

  6. Change in Pulse Rate

    Change in pulse rate from pre-intervention to post-intervention under each stimulation condition.

    Time frame: Immediately before and immediately after each 10-minute intervention session

  7. Change in Respiratory Rate

    Change in respiratory rate from pre-intervention to post-intervention under each stimulation condition.

    Time frame: Immediately before and immediately after each 10-minute intervention session

  8. Change in Subjective Discomfort Assessed by Visual Analog Scale (VAS)

    Subjective discomfort will be assessed using a Visual Analog Scale (VAS) ranging from 0 to 10, where 0 indicates no discomfort and 10 indicates the worst possible discomfort. Higher scores indicate greater discomfort. Change in VAS score from pre-intervention to post-intervention will be evaluated under each stimulation condition.

    Time frame: Immediately before and immediately after each 10-minute intervention session

07

Study locations

1 site
  • Artvin Coruh University, Artvin Vocational School, Disabled Care and Rehabilitation Laboratory
    Artvin, Turkey (Türkiye)
    • Ömer Dicle Kızıl, PT, MSc · Contactomerdiclekizil@gmail.com · +90 541523 36 91
    • Ömer Dicle Kızıl, PT, MSc · Sub investigator
08

References and documents

Publications

  • Shaffer F, Ginsberg JP. An Overview of Heart Rate Variability Metrics and Norms. Front Public Health. 2017 Sep 28;5:258. doi: 10.3389/fpubh.2017.00258. eCollection 2017. PubMed 29034226 ↗
  • Yakunina N, Kim SS, Nam EC. Optimization of Transcutaneous Vagus Nerve Stimulation Using Functional MRI. Neuromodulation. 2017 Apr;20(3):290-300. doi: 10.1111/ner.12541. Epub 2016 Nov 29. PubMed 27898202 ↗
  • Peuker ET, Filler TJ. The nerve supply of the human auricle. Clin Anat. 2002 Jan;15(1):35-7. doi: 10.1002/ca.1089. PubMed 11835542 ↗
  • Frangos E, Ellrich J, Komisaruk BR. Non-invasive Access to the Vagus Nerve Central Projections via Electrical Stimulation of the External Ear: fMRI Evidence in Humans. Brain Stimul. 2015 May-Jun;8(3):624-36. doi: 10.1016/j.brs.2014.11.018. Epub 2014 Dec 6. PubMed 25573069 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for May 2026; primary completion for May 2026, 0 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 6, 2026
First posted
Apr 13, 2026
StartEst.
May 1, 2026
Primary completionEst.
May 1, 2026
CompletionEst.
Sep 1, 2026
Last update
Apr 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07526402
Lead sponsor
Sinop University
Responsible party
SEFA HAKTAN HATIK (Assistant Professor, Sinop University) — Principal investigator
First posted
Apr 13, 2026
Start date
May 1, 2026 (estimated)
Primary completion
May 1, 2026 (estimated)
Completion
Sep 1, 2026 (estimated)
Last update
Apr 16, 2026

Study contacts

Sefa Haktan Hatık, MSc, PhD
Contact
haktanhtk@gmail.com
90 368 271 55 28

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion